Reinvention of chemotherapy: drug conjugates and nanoparticles

Current Opinion in Oncology
Tu Nguyen-Ngoc, Eric Raymond

Abstract

Recent advances in nanotechnology have addressed some of the issues related to lack of selectivity and nonspecific toxicities associated with conventional chemotherapy. Nanoparticles are therapeutic carriers that can be fine tuned for specific application and for passive or active tumor targeting. Although the nanoparticle field is rapidly expanding, there are to date only six nanoparticle-based drug delivery platforms and two antibody-drug conjugates that are clinically approved for cancer therapy. Here, we review the clinical data of liposomal anthracyclines, nanoparticle formulations of paclitaxel and trastuzumab emtansine. We then briefly comment on efficacy and safety issues of nanoparticles, as well as on the next-generation nanoparticles for cancer therapy. The emerging development of cancer nanotechnology offers the opportunity of reinvestigating the potential of cytotoxic agents, improving tumor targeting and drug delivery, leading to better safety profile and antitumor activity. Adding specificity to nanoparticles may allow personalization of cancer therapy using chemotherapy.

References

Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D PapahadjopoulosC Redemann
Jul 11, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B WeissB Leyland-Jones
Oct 4, 1989·Journal of the National Cancer Institute·A GabizonD Papahadjopoulos
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B UzielyA Gabizon
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillA M Levine
Jul 1, 1996·Annals of Internal Medicine·K ShanJ B Young
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzB Winograd
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillM E Ross
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·A SparreboomO van Tellingen
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S SjögrenJ Bergh
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W NorthfeltD H Henry
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
May 3, 2000·Lancet·J Crown, M O'Leary
Oct 19, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T SafraA Gabizon
Mar 30, 2001·European Journal of Biochemistry·K PaálL Hegedûs
Apr 3, 2001·Nature Biotechnology·R Weissleder
Jun 8, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·S C KimM H Seo
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H GelderblomA Sparreboom
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Feb 2, 2002·American Journal of Clinical Oncology·Eric RosenthalUNKNOWN DNX Study Group
Dec 10, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·Theresa A JohnRichard D Minshall
May 13, 2003·Clinical Pharmacokinetics·Alberto GabizonYechezkel Barenholz
Jan 8, 2004·Chemical & Pharmaceutical Bulletin·John M CassadyEckhard Leistner
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E R O'BrienUNKNOWN CAELYX Breast Cancer Study Group
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y MatsumuraK Takahashi
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tae-You KimYung-Jue Bang
Aug 24, 2004·Cancer Chemotherapy and Pharmacology·Klaus MrossChristine E Swenson
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ChanL W Lee
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan M KellerCraig Tendler
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaParviz Ghahramani
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alex SparreboomNeil Desai
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W NymanDaniel D Von Hoff

❮ Previous
Next ❯

Citations

Feb 20, 2016·Oncotarget·Kamini SewdaDavid L Morse

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

Related Papers

Annual Review of Medicine
Andrew Z WangOmid C Farokhzad
Journal of Controlled Release : Official Journal of the Controlled Release Society
Charlene M DawidczykPeter C Searson
Annals of the New York Academy of Sciences
Mauricio LealOmar Kabbarah
© 2021 Meta ULC. All rights reserved